Free water imaging is an advanced diffusion magnetic resonance imaging approach that attempts to separate the diffusion signal arising from brain tissue from the signal contributed by freely diffusing water in the extracellular space. In principle, the method quantifies a ‘free water fraction,’ a scalar measure that rises when extracellular fluid accumulates. Because neuroinflammation, cell loss, and tissue degeneration are all thought to expand the extracellular space, an elevated free water fraction has been interpreted by many groups as a proxy for neurodegenerative change. The nigrostriatal system, the midbrain circuitry that deteriorates in Parkinson’s disease, has been the principal target of these measurements, and numerous studies have reported elevated free water in the substantia nigra of patients compared with healthy controls.

The appeal of the technique is easy to understand. Parkinson’s disease remains a clinical diagnosis, supported by dopamine transporter imaging and response to levodopa, yet the field has long lacked a biomarker that tracks the underlying biology over time. Clinical rating scales are influenced by medication, symptom fluctuation, and rater variability. Structural atrophy measures change slowly and nonspecifically. Against this backdrop, a diffusion metric that appears sensitive to microstructural change in the substantia nigra, potentially within a single scanning session and without ionizing radiation or contrast agents, has generated considerable enthusiasm, including as a candidate progression biomarker in therapeutic trials.

That enthusiasm, however, has collided with a persistent methodological problem: the free water signal is extraordinarily sensitive to how the data are acquired and processed. The model underlying free water imaging fits a two-compartment representation to diffusion-weighted signals, and this fitting problem is ill-conditioned, meaning that small perturbations in image quality, noise, motion, or gradient performance can shift the estimated free water fraction by amounts comparable to the group differences reported in disease studies. Echo-planar imaging distortions, eddy currents, subject head motion, and even the choice of preprocessing pipeline can leave systematic fingerprints on the resulting maps. Critics have argued that some reported patient-control differences may reflect these technical confounds rather than genuine biology.

The critique that prompted the reply appears to press exactly this point, arguing that free water findings in Parkinson’s disease should not be treated as a binary verdict, for or against the method, but that the method itself matters decisively. The phrase ‘not a binary verdict’ suggests a call for nuance: the question is not simply whether free water imaging works, but under which acquisition protocols, preprocessing choices, and analysis pipelines it can be trusted, and where its limits lie. The reply, published in the same journal, represents the original authors’ defense of their approach and their response to the methodological objections raised.

Debates of this kind are not academic quibbles. If free water imaging is adopted as a secondary or exploratory endpoint in clinical trials, systematic measurement error could obscure true disease slowing, inflate apparent effect sizes, or generate spurious signals that misdirect therapeutic programs. Conversely, if genuine biological signal exists and is dismissed because of technical skepticism, the field may abandon a useful window into neuroinflammation and tissue integrity. The stakes are amplified by the broader push toward biomarker-based staging of Parkinson’s disease, exemplified by recent biological definitions of the disease that incorporate alpha-synuclein seed amplification assays and other molecular measures. Imaging markers that complement these fluid biomarkers would be valuable, but only if their measurement properties are rigorously characterized.

Methodological scrutiny of free water imaging has intensified in recent years. Studies have examined the test-retest reliability of the measure, the influence of scanner vendor and field strength, and the reproducibility of findings across independent cohorts. Some analyses have found that free water elevations in the substantia nigra are robust and correlate with clinical severity, while others have reported that apparent effects diminish or change direction when alternative preprocessing pipelines are applied. Multi-site harmonization efforts have highlighted the difficulty of pooling free water estimates across scanners, and work in other neurological conditions has shown that the metric can be confounded by factors as mundane as ventricular proximity and as consequential as prior imaging artifacts.

Within this contested landscape, the exchange in npj Parkinson’s Disease illustrates how the field is negotiating standards. Replies and counter-replies of this sort serve a function beyond the immediate dispute: they force researchers to articulate the assumptions of their models, the sensitivity analyses they performed, and the conditions under which their conclusions hold. For readers and clinicians, the practical takeaway is that a free water fraction reported in a paper is not a universal constant but the output of a specific acquisition and analysis chain. Comparing values across studies without accounting for those chains risks comparing apples to oranges, a caution that applies to many advanced diffusion techniques, including neurite orientation dispersion and density imaging and related microstructural models.

For patients and families, the debate may seem remote, but its consequences are concrete. Biomarkers determine who is enrolled in trials, when treatments are judged to work, and how quickly disease-modifying therapies reach the clinic. A reliable imaging marker of nigral degeneration could shrink trial sizes, shorten durations, and enable earlier intervention, which is why the National Institutes of Health and the Parkinson’s community have invested heavily in biomarker validation programs. The current exchange should be read as part of that validation process: an insistence that before free water imaging is elevated to a verdict on disease progression, the method must demonstrate that its signal is separable from its noise.

The publication of the reply, alongside the critique it addresses, gives the research community and interested readers an unusually transparent view of a scientific disagreement in progress. Both documents are openly accessible through the journal, allowing independent readers to weigh the arguments for themselves. Whatever the resolution, the episode underscores a principle that extends well beyond this single technique: in neuroimaging, the method matters, and the credibility of any biomarker rests on the reproducibility of the pipeline that produces it. As free water imaging continues to be tested in longitudinal cohorts and interventional studies, exchanges like this one will help determine whether it earns a durable place in the Parkinson’s disease toolkit or remains a promising but contested research measure.

Subject of Research: Free water diffusion imaging as a biomarker of neurodegeneration and disease progression in Parkinson's disease

Article Title: Reply to ‘The method matters: free water imaging in Parkinson’s disease is not a binary verdict’

Article References: Roh, Y. H., Youn, J., Kim, S.-Y., Heo, H., Song, S., & Sohn, B. (2026). Reply to ‘The method matters: free water imaging in Parkinson’s disease is not a binary verdict’. npj Parkinson's Disease, 12(1), Article 218. https://doi.org/10.1038/s41531-026-01490-w

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01490-w

Keywords: Parkinson's disease, free water imaging, diffusion MRI, biomarkers, substantia nigra, neurodegeneration, npj Parkinson's Disease, neuroimaging, clinical trials, methodology, test-retest reliability, nigrostriatal degeneration

The study, conducted by researchers at The Affiliated Hospital of Qingdao University and published in the Journal of Ovarian Research, systematically mined the ClinicalTrials.gov registry for ovarian cancer vaccine trials registered between 1996 and June 2026. The team extracted and analyzed data on study phase, recruitment status, enrollment size, geographic distribution, funding source, vaccine platform, combination strategy, clinical context, and endpoint selection. Their findings paint a detailed portrait of a field that has sustained momentum since the mid-1990s but has yet to translate that activity into approved therapies.

The numbers tell a striking story. The 136 unique studies collectively involved 4,180 participants. Nearly half of all trials, 48.53 percent, were Phase I studies, while 23.53 percent were Phase II and 21.32 percent were combined Phase I/II designs. Only two Phase III trials appeared in the entire registry. Completion rates were moderate, with 55.88 percent of studies finished, but transparency lagged far behind: just 22.79 percent of trials had publicly posted results. Geographically, the United States dominated the landscape, participating in 105 of the registered studies, reflecting the concentration of immunotherapy infrastructure and funding in American academic and industry centers.

On the technical side, the analysis identified five major vaccine platforms competing for dominance. Peptide and antigen vaccines, which deliver synthetic fragments of tumor-associated proteins to prime immune responses, formed the largest category. Dendritic cell vaccines, in which a patient’s immune cells are harvested, loaded with tumor antigens in the laboratory, and reinfused to act as powerful antigen-presenting scouts, represented another major approach. Whole tumor cell or lysate vaccines offer the advantage of presenting the full antigenic repertoire of a patient’s tumor, while DNA and RNA vaccines instruct the patient’s own cells to produce tumor antigens in situ. Viral and vector vaccines use engineered viruses to deliver tumor antigens and provoke strong cellular immunity. Each platform carries distinct advantages in manufacturing complexity, antigen breadth, and the type of immune response it preferentially elicits.

The mechanistic logic underlying all these platforms is the same: break immune tolerance to tumor antigens and generate durable populations of cytotoxic T lymphocytes capable of recognizing and killing ovarian cancer cells. Common antigenic targets across trials have included Wilms tumor 1, p53, and antigens associated with BRCA-mutated tumors, alongside the widely monitored biomarker CA-125. Adjuvants such as granulocyte-macrophage colony-stimulating factor have frequently been deployed to supercharge dendritic cell activation, and human leukocyte antigen typing has shaped patient eligibility in many peptide-based studies, since vaccine peptides must be presented on specific MHC molecules to be seen by T cells.

Perhaps the most important trend the analysis uncovered is a decisive shift away from single-agent vaccination toward combination strategies. Modern trials increasingly pair therapeutic vaccines with immune checkpoint inhibitors such as antibodies targeting PD-1, PD-L1, or CTLA-4, which release the molecular brakes that tumors place on T cells. Others combine vaccines with chemotherapy, exploiting the ability of certain cytotoxic drugs to promote immunogenic tumor cell death and antigen release, or with immune adjuvants that amplify the vaccine-primed response. This combinatorial logic mirrors the broader evolution of cancer immunotherapy, where vaccines are increasingly viewed as one component of a multi-pronged attack rather than a standalone cure.

The clinical context of these trials is also revealing. Most studies enrolled patients with advanced, metastatic, or recurrent ovarian cancer, populations with urgent unmet needs but also with tumors that have already evolved sophisticated immune evasion mechanisms. This creates a fundamental tension: the patients most likely to benefit from vaccination in principle, those with minimal residual disease after cytoreductive surgery and platinum-sensitive relapse, are underrepresented relative to heavily pretreated cohorts whose immune systems and tumor microenvironments are profoundly immunosuppressed. The authors argue that biomarker-guided patient selection will be essential to move the field forward, matching vaccine platforms to patients whose tumors express the right antigens and whose immune milieus remain permissive.

Endpoint selection emerged as another critical weakness. Safety and toxicity measures and immunogenicity readouts dominated the trial landscape, while progression-free survival, overall survival, quality of life, and biomarker-based outcomes were comparatively underrepresented. This skew reflects the exploratory nature of most studies but also highlights why so few vaccines have progressed: regulators and clinicians ultimately need evidence that vaccine-induced immune responses translate into longer survival and better lives, not merely stronger laboratory measurements. The immune monitoring data were particularly inconsistent. Although 92 trials, or 67.65 percent, reported immune response outcomes, only 58 trials, or 42.65 percent, specified the assay method used, and 34 trials described an immune domain without naming any assay at all. Techniques as varied as chromium-51 release assays, intracellular cytokine staining, fluorescence-activated cell sorting, immunohistochemistry, delayed-type hypersensitivity testing, and ELISPOT-based measurements appeared across the literature, making cross-trial comparisons nearly impossible.

This heterogeneity in immune-response reporting is more than a bureaucratic nuisance; it is a scientific bottleneck. Without prespecified, harmonized, vaccine-specific immune monitoring frameworks, the field cannot reliably determine which platforms, antigens, adjuvants, and combinations are genuinely superior. A promising response measured in one trial with one assay cannot be meaningfully compared to a disappointing result in another using a different technique. The study’s authors call for standardized monitoring protocols to be built into trial design from the outset, alongside clinically meaningful endpoints and immune-related response criteria such as irRC and iRECIST that account for the atypical response patterns seen with immunotherapies.

Looking ahead, the researchers outline a roadmap for the next decade of ovarian cancer vaccine development. Personalized vaccines, tailored to the unique mutation profile of each patient’s tumor, hold particular promise in a disease like ovarian cancer where homologous recombination deficiency and BRCA mutations generate abundant neoantigens. Large-scale, multicenter, randomized Phase II and III trials are urgently needed to convert three decades of immunological proof-of-principle into confirmatory clinical evidence. If the field can align biomarker-driven enrollment, combination immunotherapy, standardized immune monitoring, and survival-focused endpoints, the long-pursued dream of a therapeutic ovarian cancer vaccine may finally move from the registry pages of ClinicalTrials.gov into routine clinical practice.

Subject of Research: Clinical trial landscape of therapeutic vaccines for ovarian cancer

Article Title: Clinical landscape of therapeutic vaccines for ovarian cancer: current status, challenges, and future directions

Article References: Shan, Y., Wang, Q., Wan, W., Zhang, Y., & Chu, Y. (2026). Clinical landscape of therapeutic vaccines for ovarian cancer: current status, challenges, and future directions. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02253-0

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02253-0

Keywords: ovarian cancer, therapeutic vaccines, immunotherapy, clinical trials, dendritic cell vaccines, peptide vaccines, immune checkpoint inhibitors, combination immunotherapy, immune monitoring, personalized vaccines, ClinicalTrials.gov, translational research

The review, led by Ornella Gonzato with contributions from patient advocates Denise Reinke and Roger Wilson, oncologist Bernd Kasper and regulatory expert Maria Josefina Ruiz Alvarez, examines how two landmark frameworks can be operationalised in rare cancer research: the 2024 World Health Organization Guidance for best practices for clinical trials and the International Council for Harmonisation’s ICH E6(R3) Good Clinical Practice guideline. The WHO guidance articulates scientific validity, efficiency, ethical acceptability, social value, feasibility, equity and patient engagement as interdependent components of trial quality. ICH E6(R3) complements this by reframing Good Clinical Practice around quality by design and risk-proportionate oversight, emphasising critical-to-quality factors rather than box-ticking procedural compliance. Together, the authors argue, these documents shift trial governance toward principled flexibility.

The central problem is one of proportionality. When patient populations are intrinsically small and biologically fragmented, conventional fixed-sample randomised trials may impose disproportionate burdens on participants while offering only a slim probability of generating actionable knowledge. The WHO guidance explicitly ties ethical acceptability to proportionality between risk, burden and anticipated social value. Adaptive and Bayesian designs can improve efficiency while preserving methodological rigour, and the sarcoma field has become a proving ground for them. The biomarker-driven MULTISARC umbrella trial used centralised molecular profiling to allocate patients across treatment cohorts, showing how molecular stratification can enhance feasibility and interpretability even in highly fragmented populations. IMMUNOSARC employed a multicohort, single-arm design spanning multiple rare subtypes, illustrating how flexible, risk-proportionate approaches can support evidence generation when conventional randomisation is simply impractical.

But methodological innovation alone is not enough. The review emphasises that rare cancer research depends on collaborative infrastructure that often matters as much as the trial design itself. Cross-border networks such as the European Reference Network EURACAN and international sarcoma consortia enable accrual, harmonise standards and safeguard data quality. Multinational trials such as RAIN-3201, an international randomised phase III study, and rEECur, an international multi-arm seamless phase II/III trial in relapsed and refractory Ewing sarcoma, relied on coordinated governance, harmonised data collection and cross-border recruitment to maintain scientific validity while maximising the number of patients enrolled. In populations fragmented across dozens of subtypes, such infrastructures are frequently a prerequisite for adequately powered studies rather than a mere facilitator of research activity.

Equity emerges as a persistent tension throughout the analysis. Centralising expertise improves diagnostic accuracy and outcomes, but it can raise barriers to research participation. Travel burdens, financial costs and logistical complexity fall disproportionately on patients in rural regions, lower socioeconomic groups and older populations. Regulatory heterogeneity compounds the problem: in multinational rare cancer studies, variation in approval timelines, submission requirements and local governance procedures delays site activation and creates unequal opportunities for participation across countries. These asymmetries fall hardest on academic and investigator-initiated studies, which typically lack dedicated regulatory affairs departments. The authors point to ECRIN’s Regulatory and Ethical Database, which catalogues country-specific requirements across more than 750 searchable fields, as a practical tool for navigating this fragmentation, but they stress that differences in ethics committee composition, review timelines and national procedures persist alongside the EU’s Clinical Trials Information System harmonisation.

Decentralised and hybrid trial models offer a partial remedy. Remote informed consent, telemedicine visits, electronic patient-reported outcomes, local clinical assessments, remote monitoring and digital data capture can reduce the burden of participation for geographically dispersed patients, improving recruitment and retention. Registry-based initiatives such as RESAR, a prospective multicentre sarcoma registry, and ICONIC, a registry-based osteosarcoma platform with strong patient involvement, demonstrate how longitudinal real-world data collection can complement interventional studies, support external control arms when randomisation is infeasible and give researchers contextual evidence grounded in patient experience. The authors caution, however, that decentralisation should extend rather than replace specialist centres, and that digital-first approaches require infrastructure, regulatory alignment, data protection safeguards and explicit attention to digital inclusion so that efforts to improve accessibility do not unintentionally exclude under-resourced populations.

Patient-centredness, the review argues, is not merely an ethical nicety but a structural determinant of what the authors call operational validity—the ability of a trial to generate interpretable evidence under the real-world constraints of population size, feasibility and participation. In sarcomas, endpoints such as functional preservation and long-term toxicity may matter more to patients than short-term tumour response. The randomised multicentre surgical trial SarcoSIGHT shows that integrating functional and quality-of-life endpoints early in trial design is feasible while maintaining scientific rigour. Structured involvement of advocacy organisations such as the Sarcoma Patient Advocacy Global Network in protocol development, consent processes and dissemination enhances both feasibility and interpretability in very small populations, and patient-led initiatives like ICONIC demonstrate how engaged communities can shape research agendas and sustain engagement over time.

Digital and artificial intelligence-enabled tools extend this agenda further. Applications under active exploration include AI-assisted patient identification from electronic health records, wearable-based remote monitoring and digital twins as synthetic control alternatives—particularly relevant where randomising patients to a control arm is statistically or ethically constrained in ultra-rare populations. The WHO’s Global Action Plan for Clinical Trial Services calls for adopting such innovative designs and technologies to improve recruitment, data collection, analysis and oversight, while the Global Clinical Trials Forum provides the institutional architecture for aligning digital governance standards across jurisdictions. Yet the authors insist the governance risks demand equal attention: algorithmic bias can reproduce geographic and socioeconomic inequities in participant selection, unequal digital access can exclude vulnerable groups, and opaque AI-assisted decisions in eligibility or safety monitoring require audit trails and human oversight embedded by design.

The cross-cutting lessons are strikingly consistent. Methodological flexibility succeeds when linked to clear biological rationale, not innovation for its own sake. Feasibility and scientific validity are inseparable, because recruitment failure and attrition can render even a methodologically sound trial inconclusive. International collaborative infrastructure is an enabling condition, not a luxury. Patient-centred approaches improve operational performance, not just ethical acceptability. And despite all this progress, regulatory fragmentation remains the stubborn barrier that governance frameworks must address with greater specificity. The WHO Global Action Plan’s sixth action on streamlining regulatory and ethics review will need teeth if equitable, multinational rare cancer trials are to become routine rather than exceptional.

The implications reach well beyond sarcomas. As molecular stratification carves common cancers into progressively smaller and more dispersed subsets, the governance lessons forged in rare cancer research are increasingly relevant to precision oncology at large. The authors identify outstanding questions that will define the next decade: how to translate principles into proportionate governance across diverse regulatory systems, how to combine adaptive designs, registries, real-world data and decentralised models optimally, how to integrate patient involvement into regulatory decision-making, how to deploy digital tools equitably and transparently, and what sustainable funding models can maintain international research infrastructures. The review is candid about its limitations—it is a structured narrative synthesis, examples are illustrative rather than exhaustive, most evidence comes from high-income settings, and direct causal evidence linking patient engagement practices to trial outcomes remains limited. But its core message is clear: in rare cancers, operational validity depends on the interaction of methodological innovation, collaborative infrastructure, patient-centred governance and proportional regulation, and sarcoma research has shown the way.

Subject of Research: Patient-centred clinical trial design and governance for rare cancers, using sarcomas as a model for applying 2024 WHO guidance and ICH E6(R3)

Article Title: Patient-centred and fit-for-purpose clinical trials in rare cancers: lessons from sarcomas for operationalising 2024 WHO Guidance and ICH E6(R3)

Article References: Gonzato, O., Reinke, D., Wilson, R., Kasper, B., & Ruiz Alvarez, M. J. (2026). Patient-centred and fit-for-purpose clinical trials in rare cancers: lessons from sarcomas for operationalising 2024 WHO Guidance and ICH E6(R3). eClinicalMedicine, 100, Article 104192. https://doi.org/10.1016/j.eclinm.2026.104192

Image Credits: AI Generated

DOI: 10.1016/j.eclinm.2026.104192

Keywords: rare cancers, sarcoma, clinical trials, WHO guidance, ICH E6(R3), adaptive trial design, patient engagement, decentralised trials, real-world data, regulatory harmonisation, operational validity, precision oncology

DCIS, a non-invasive condition in which abnormal cells are confined to the milk ducts, accounts for roughly one in four breast cancers detected through screening programmes. Standard treatment options include mastectomy or breast-conserving surgery (BCS), with or without adjuvant radiotherapy, and in some cases endocrine therapy with drugs such as tamoxifen or aromatase inhibitors to reduce the risk of recurrence. Because approximately 65 to 80 percent of DCIS lesions are oestrogen receptor positive, knowing a tumour’s ER status is central to deciding whether hormone therapy is appropriate. Yet, as the new study demonstrates, ER testing for DCIS was performed in only 15.4 percent of the 5,813 women included in the cohort.

The researchers drew their data from the Breast Cancer Foundation National Register, which began collecting information in Auckland and Waikato in 2000, expanded to Christchurch in 2009 and Wellington in 2010, and achieved nationwide coverage only from 2020 onwards. By linking the register to New Zealand’s national Pharmaceutical Collection database through encrypted National Health Index numbers, the team could identify who was dispensed tamoxifen or aromatase inhibitors after a DCIS diagnosis. Statistical analyses employed multivariable logistic regression to identify factors associated with ER testing and cumulative incidence functions, with death treated as a competing risk, to estimate the probability of breast cancer events over time.

The headline finding is geographic. Of the 894 women who had an ER test on record, 65.6 percent were treated in the Waikato region, home to a well-established breast cancer research infrastructure and one of New Zealand’s two original breast screening pilot programmes. In Waikato, ER testing rose sharply from 35 percent in the late 1990s to 82.4 percent by 2003 and remained high, reaching 84.8 percent in 2022. Everywhere else, testing stayed stubbornly low, creeping from just 4.5 percent in 2000 to 7.1 percent in 2022. The investigators attribute Waikato’s exceptional performance to the participation of local clinical centres in international trials evaluating endocrine therapy for DCIS, including the UK/ANZ DCIS trial and the IBIS-II DCIS trial, which exposed clinicians there to the evidence base early and embedded testing into routine care.

The factors associated with receiving an ER test also differed dramatically by region, offering a window into contrasting models of care. In Waikato, women who received adjuvant radiotherapy after breast-conserving surgery were more likely to be tested, a pattern the authors interpret as reflecting local protocols that promoted both treatments in tandem rather than selective ordering by individual clinicians. Elsewhere in the country, testing appeared highly selective: older women, Māori women, those presenting with symptoms rather than through screening, and those with larger DCIS lesions exceeding 20 millimetres were more likely to be tested, suggesting clinicians ordered the test only when they believed the result would influence management. Nationally, the overall testing rate rose from 11.1 percent in 2000 to a peak of 23.3 percent in 2006 before drifting back down to 13.9 percent in 2022.

Among the 729 women whose DCIS was confirmed as ER positive, only 183, or 25.1 percent, actually initiated endocrine therapy, and more than 80 percent of those initiations occurred in Waikato. Tamoxifen was the most common first-line treatment, used by 58.5 percent of women starting therapy, followed by aromatase inhibitors at 38.3 percent. Consistent with shifts seen internationally after the NSABP B-35 trial suggested anastrozole outperformed tamoxifen in postmenopausal women, aromatase inhibitor use in Waikato climbed steadily, exceeding tamoxifen after 2018 and rising from 12.5 percent of initiations in the mid-2000s to 55 percent by 2022. Overall initiation of endocrine therapy in Waikato grew from 20 percent in 2000–2001 to 62.5 percent in 2022.

Does the hormone therapy actually help? After a median follow-up of 4.8 years, women with ER-positive DCIS who received endocrine therapy showed the lowest cumulative risk of any breast cancer event, but the differences between groups did not reach statistical significance, likely because the number of treated patients and events was simply too small to detect a benefit. The authors caution that these results do not exclude a clinically meaningful effect. Supporting evidence from prior research suggests that good adherence reduces recurrence, that at least two years of treatment decreases second breast events, and that adding endocrine therapy to breast-conserving surgery lowers the risk of subsequent invasive breast cancer compared with surgery alone. For a subset of Waikato women with documented therapy use of at least two years, the five-year cumulative incidence of a breast cancer event was just 6.3 percent, though this estimate rested on very few events.

The international context makes New Zealand’s numbers stand out even more sharply. In the United States, ER testing for DCIS surged from 17.5 percent in the early 2000s to 93.1 percent by 2012–2014, propelled by the 2000 approval of tamoxifen for DCIS following the NSABP B-24 trial. European testing rates range from 30 to 85 percent. Since 2020, both the ASCO/CAP guideline and the National Comprehensive Cancer Network have recommended ER testing for all DCIS patients to guide endocrine therapy decisions. New Zealand’s own early breast cancer guideline, last updated in 2009, recommends endocrine therapy for ER-positive invasive cancers but leaves the decision for ER-positive DCIS to individual circumstances, leaving clinicians without a clear national mandate for testing.

The study’s authors argue that the regional variation they documented is not an argument for exporting Waikato’s model wholesale, but rather evidence that nationally consistent guidelines and clinical pathways are urgently needed. Without standardised ER testing, they note, clinicians and patients cannot make informed decisions about whether the potential recurrence-reduction benefits of endocrine therapy, weighed against side effects such as aromatase inhibitor-related musculoskeletal symptoms, are worth pursuing in an individual case. Options such as low-dose tamoxifen, which showed comparable efficacy with improved tolerability in the TAM-01 trial, may widen the appeal of treatment for patients prioritising quality of life. Greater clinician participation in clinical trials, the researchers suggest, could simultaneously strengthen local evidence and keep practitioners engaged with emerging data.

Limitations temper some conclusions. Registry data capture began at different times in different regions, and nationwide coverage was achieved only in 2020, making endocrine therapy initiation numbers outside Waikato too sparse for trend analysis. Patient preferences regarding adjuvant therapy were unavailable, and the observed higher likelihood of testing among Māori women outside Waikato may reflect unmeasured local practice patterns rather than true differences in tumour biology. Nevertheless, as the first population-based study of ER testing and endocrine therapy for DCIS in New Zealand, the work delivers a clear message: a two-decade evidence gap persists in routine care, and closing it will require updated national guidelines, standardised receptor testing, and a broader culture of clinical research participation to ensure that women with DCIS everywhere benefit from treatments proven in trials.

Subject of Research: Oestrogen receptor testing and adjuvant endocrine therapy use in ductal carcinoma in situ in New Zealand

Article Title: Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study

Article References: Oestrogen receptor testing and initiation of adjuvant endocrine therapy in women with ductal carcinoma in situ: a population-based study. (n.d.). https://doi.org/10.1007/s10549-026-08072-7

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08072-7

Keywords: ductal carcinoma in situ, oestrogen receptor testing, endocrine therapy, tamoxifen, aromatase inhibitors, breast cancer, New Zealand, regional variation, population-based study, clinical trials, recurrence, guidelines

Melflufen, also known as melphalan flufenamide, is a peptide-drug conjugate designed to deliver an alkylating payload preferentially into myeloma cells by exploiting peptidase activity within the tumor microenvironment. The OCEAN trial compared melflufen-dexamethasone against pomalidomide-dexamethasone in patients with relapsed or refractory disease, while HORIZON evaluated melflufen in heavily pretreated patients. The current European approval restricts melflufen use to patients who have not undergone autologous stem cell transplant or whose time to progression is three years or more, a restriction grounded in a post-hoc analysis of OCEAN showing that patients with a time to progression under 36 months fared significantly worse on melflufen than on the comparator, with median overall survival of 15.7 versus 28.7 months and a hazard ratio of 1.8 that reached statistical significance.

The commentators focus their first major criticism on Patient 1 from the case series, whose time to progression after autologous stem cell transplant was 28 months, placing this individual squarely within the subgroup that the OCEAN post-hoc analysis identified as being disadvantaged by melflufen treatment. The original paper acknowledged this discrepancy only briefly, noting that the long duration of response occurred despite the unfavorable time to progression. Bhise and colleagues contend that this framing creates a subtle but consequential problem: a single case with an atypically favorable outcome is being used to soften the message about a subgroup that randomized trial evidence indicates is harmed, on average, by this treatment relative to the alternative. They emphasize that case reports are inherently susceptible to selective emphasis because exceptional outliers are precisely what prompt such reports in the first place.

The statistical logic underlying this criticism reflects a well-known pitfall in clinical evidence interpretation. Subgroup analyses of randomized trials estimate average effects within defined patient populations, and individual outcomes within any subgroup can deviate dramatically from that average without invalidating the population-level finding. When a case report highlights an outlier who thrived despite belonging to a subgroup that trial data show is disadvantaged, presenting that case alongside arguments for extending treatment to patients outside the approved population risks leaving readers with the impression that individual favorable responses can offset subgroup-level harm demonstrated in a randomized comparison. The commentators argue that explicitly restating, within the discussion of this specific case, that the OCEAN subgroup data indicate a significant survival disadvantage for similar patients would prevent the exceptional case from being misread as evidence against the very population-level finding it contradicts.

The second major criticism concerns the safety data used to reassure readers about the risk of second primary malignancies. Patient 1 received 46 cycles of melflufen-dexamethasone over approximately four years before developing a second primary myelodysplastic neoplasm, a type of bone marrow disorder that can progress to acute leukemia. The original authors attributed this malignancy largely to the patient’s prior exposure to alkylating agents and immunomodulatory drugs, citing the low reported rate of second primary malignancies across the HORIZON and OCEAN trials as reassurance about melflufen’s own mutagenic contribution. The commentators find this reassurance statistically unsound for a specific and important reason rooted in the relationship between cumulative exposure and carcinogenic risk.

That reason is exposure duration. The median progression-free survival among trial responders was 8.5 months in both study populations, meaning that most trial patients received only a small fraction of the cumulative melflufen exposure that Patient 1 accumulated before the malignancy developed. Cumulative-dose-related carcinogenesis is a well-established feature of alkylating agents, and the commentators point out that the trial population’s exposure was systematically too brief to detect such a risk even if it existed. A second primary malignancy rate calculated from a population whose treatment was, on average, cut short after several months by disease progression or intolerance therefore provides limited reassurance about mutagenic risk in patients who go on to receive several years of continuous alkylating exposure. Because the original discussion favors considering melflufen for extended use in exceptional responders, the very population capable of accumulating multi-year exposure, the safety reassurance drawn from short-exposure trial populations does not address the risk profile most relevant to the patients the recommendation would actually affect.

The commentators propose a concrete methodological remedy: reporting cumulative melflufen dose or treatment duration alongside second primary malignancy incidence, where such data are available from trial extensions or real-world follow-up, would provide a more directly applicable estimate of risk for long-term responders being considered for extended therapy. This recommendation aligns with broader principles in oncology pharmacovigilance, where the relevance of safety signals depends critically on matching the exposure profile of the safety data to the exposure profile of the patients in question. Similar concerns about second primary malignancies have been raised in other novel therapy contexts, including systematic reviews of malignancy risk following CAR T-cell therapy, underscoring that long-duration follow-up is essential whenever powerful cytotoxic or immunologic treatments achieve durable disease control.

Despite these pointed criticisms, the commentary is not a rejection of the original work. Bhise and colleagues explicitly acknowledge that the case series offers a genuinely useful clinical contribution by illustrating that meaningful, durable responses to melflufen-dexamethasone are achievable in carefully selected patients. They note that such granular, longitudinal case detail complements population-level trial reporting in ways that aggregate statistics cannot, capturing the clinical course of individual patients over years of treatment. They also credit the original authors with appropriate transparency for explicitly acknowledging that the cases were retrospectively selected for their exceptional duration of response, an admission that properly frames the study’s inherent selection bias. This balanced tone reflects a growing recognition in the medical literature that case reports retain value precisely when their limitations are stated plainly and their conclusions are calibrated to the strength of the evidence.

The clinical implication drawn by the commentators is direct and specific. Before these exceptional cases inform practical guidance about extending melflufen use beyond the currently approved target population or into multi-year continuous therapy, two reconciliations are needed. First, the discussion of Patient 1 should explicitly confront the unfavorable OCEAN subgroup data for patients with a time to progression under 36 months, rather than allowing a favorable outlier to stand in implicit tension with randomized evidence. Second, reassurance about second primary malignancy risk during extended use should be grounded in exposure-matched safety data rather than incidence rates drawn from a trial population whose average treatment duration was substantially shorter. Until those conditions are met, the commentators suggest, the exceptional responses should be viewed as intriguing observations rather than as a basis for broadening treatment recommendations.

The exchange highlights a broader lesson for the era of precision oncology and expanding immunotherapies. As treatment landscapes grow more complex, with novel agents such as antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies entering practice alongside older cytotoxic backbones, the temptation to generalize from spectacular individual responses will only increase. The commentary by Bhise, Akotkar, Bhandari, and Gite serves as a reminder that the evidentiary weight of a case report is bounded by the statistics of the trials that contextualize it, and that safety conclusions are only as strong as the exposure profiles on which they rest. For patients with relapsed or refractory multiple myeloma, a disease where treatment sequencing decisions carry profound survival consequences, the difference between an exceptional anecdote and population-level evidence can be a matter of years of life, making rigorous interpretation of both not an academic nicety but a clinical imperative.

Subject of Research: Critical appraisal of melflufen-dexamethasone case reports for relapsed/refractory multiple myeloma

Article Title: Comment on “Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?”

Article References: Bhise, M. R., Akotkar, A., Bhandari, S., & Gite, K. V. (2026). Comment on “Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?”. Journal of Cancer Research and Clinical Oncology, 152(9), Article 176. https://doi.org/10.1007/s00432-026-06608-4

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06608-4

Keywords: melflufen, dexamethasone, multiple myeloma, OCEAN trial, HORIZON trial, relapsed/refractory myeloma, second primary malignancy, subgroup analysis, case report, alkylating agents, clinical trials, oncology

Bacteriophages, the viruses that infect and kill bacteria, were first explored as therapeutic agents in the early twentieth century, shortly after their discovery by Frederick Twort and Félix d’Hérelle. While Western medicine largely abandoned the approach after the arrival of antibiotics, parts of Eastern Europe and the former Soviet Union never stopped using it. The new review, authored by a large consortium of researchers led by Roman Pantůček and Jiří Doškař of Masaryk University in Brno, documents how the Czech lands participated in this long tradition and how that historical foundation has been systematically rebuilt and modernized since the year 2000.

The review’s authors describe a national ecosystem in which academic institutions, biotechnology companies, and university hospitals work in parallel rather than in isolation. According to their analysis, more than 30 competitively funded research projects have been launched in the Czech Republic since 2000, addressing the central technical challenges that stand between laboratory phage research and routine clinical use. These projects have tackled phage safety assessment, genomic characterization of therapeutic candidates, formulation and delivery strategies, synergy between phages and conventional antibiotics, and the difficult problem of manufacturing phage preparations under Good Manufacturing Practice, the regulatory quality standard required for medicines.

The technical depth of this national effort is considerable. Genomic characterization, for example, is now understood as a non-negotiable prerequisite for any phage intended for human use, since phage genomes can harbor toxin genes or other undesirable cargo, and whole-genome sequencing allows candidate viruses to be screened before they ever reach a patient. The Czech teams have applied these methods extensively to staphylococcal phages, an area in which Masaryk University researchers have long specialized, reflecting the country’s historical focus on Staphylococcus aureus infections and conditions such as osteomyelitis, a stubborn bone infection that is notoriously difficult to treat with antibiotics alone and where topical phage preparations such as the long-standing Czech product Stafal found early application.

Stafal itself occupies an important place in the review’s historical narrative. Developed and produced in Czechoslovakia for decades, the staphylococcal phage preparation was used in the treatment of bacterial infections and became one of the few phage products in Europe with continuous production and clinical availability across the political upheavals of the twentieth century. Its survival into the modern era gave Czech researchers and clinicians a continuity of practical experience that few other Western or Central European countries can claim, and it served as a bridge between the empirical phage medicine of the past and today’s evidence-based, molecularly characterized approaches.

Clinical translation is now advancing along two complementary tracks. The first is treatment on a named-patient basis, a compassionate framework that allows physicians to administer phage preparations to individual patients with severe, otherwise untreatable infections, often under national regulations that accommodate unlicensed medicines when no authorized alternative exists. The second track consists of formal clinical trials, which the review describes as ongoing. Moving from anecdotal case reports to controlled studies is widely regarded by the phage therapy community as the decisive step toward regulatory acceptance, and the Czech combination of clinical partners and domestic GMP-compliant production places the country in a strong position to generate the kind of standardized evidence that regulators require.

The review also emphasizes that the Czech phage effort extends well beyond human medicine. In veterinary practice, phages have been investigated as alternatives to antibiotics in livestock, where reducing antimicrobial use has become a priority both for controlling resistance and for meeting European policy targets. In agriculture, researchers have explored phage-based biocontrol of plant pathogenic bacteria, an application studied at the Czech Academy of Sciences’ plant virology institute in České Budějovice. Food safety represents a third area of application, with phages offering a way to reduce pathogenic bacteria on food products without chemical residues. Together these sectors demonstrate a breadth of phage expertise that reinforces the human medicine pipeline, since methods for phage isolation, characterization, and formulation are largely transferable across applications.

Structural biology has added a distinctive dimension to the national program. At the Central European Institute of Technology in Brno, researchers including Pavel Plevka and Tibor Füzik apply cryo-electron microscopy to determine the atomic structures of phage particles, revealing how these viruses recognize their bacterial hosts and deliver their genetic material. Such structural insight is increasingly relevant to rational phage engineering, in which viruses are modified to broaden their host range, evade bacterial defense systems, or improve their stability in pharmaceutical formulations. The presence of world-class structural biology alongside classical phage biology and industrial production is precisely the kind of interdisciplinary integration the review identifies as a national strength.

Looking forward, the authors identify several priorities that will determine whether Czech phage therapy can move from promising practice to sustainable standard of care. Sustainable access to standardized phage preparations is paramount: phage therapy is inherently individualized, because phages must be matched to the specific bacterial strain infecting each patient, and bacteria can evolve resistance to individual phages, so therapeutic preparations typically consist of carefully designed cocktails of multiple viruses. Maintaining libraries of well-characterized phages, updating them in response to evolving bacterial populations, and producing them reproducibly under GMP conditions is logistically and financially demanding in ways that conventional small-molecule antibiotics are not. The review argues that this challenge must be addressed within the rapidly evolving European regulatory framework, which is only now beginning to define how individualized biological therapies should be assessed, authorized, and reimbursed.

The broader significance of the Czech experience extends across the continent. As antimicrobial resistance is projected to cause millions of deaths annually in the coming decades, European health systems are actively searching for non-traditional antibacterial therapies, including enzybiotics, phage-derived enzymes that degrade bacterial cell walls, alongside whole-phage treatments. The review’s conclusion is that the Czech Republic has established the substantial expertise and infrastructure needed to serve as an important European contributor to this effort, offering a working model of how a long national tradition, when combined with modern genomics, structural biology, regulatory engagement, and industrial capability, can be transformed into a coherent pathway for integrating phage-based interventions into twenty-first-century healthcare.

Subject of Research: Phage therapy research, clinical practice, and development in the Czech Republic as a contribution to phage therapy in Europe

Article Title: Past and present phage therapy research and practice in the Czech Republic – contribution to phage therapy in Europe

Article References: Pantůček, R., Doškař, J., Boštík, J., Kocourková, D., Petrzik, K., Koptíková, J., Benešík, M., Plevka, P., Füzik, T., Mašlaňová, I., Botka, T., Nepeřený, J., Zeller, D., Kuntová, L., Snopková, K., Hrala, M., & Moša, M. (2026). Past and present phage therapy research and practice in the Czech Republic – contribution to phage therapy in Europe. Virology Journal. https://doi.org/10.1186/s12985-026-03296-x

Image Credits: AI Generated

DOI: 10.1186/s12985-026-03296-x

Keywords: phage therapy, bacteriophages, antimicrobial resistance, Czech Republic, Staphylococcal infections, Stafal, GMP manufacturing, clinical trials, enzybiotics, biocontrol, osteomyelitis, phage-antibiotic synergy

Bruton tyrosine kinase, or BTK, sits at a critical junction in the B-cell receptor signaling pathway, and blocking it cripples the survival machinery of malignant lymphocytes. The first-generation inhibitor ibrutinib proved the concept, improving progression-free survival in relapsed or refractory disease, but its off-target activity produced troublesome cardiac events, bleeding, and other toxicities. Second-generation inhibitors zanubrutinib and acalabrutinib were engineered for greater selectivity, and clinical momentum has been rapid: acalabrutinib combined with bendamustine and rituximab recently earned preferred first-line status in the NCCN 2025 guideline after the ECHO trial demonstrated a complete response rate of 88.9 percent and a median progression-free survival of 28.6 months, while zanubrutinib gained a first-line indication restricted to TP53-mutant disease after Phase II trials recorded complete response rates of 88 percent in that high-risk cohort. Yet guidelines remained fragmented, because trial designs varied so widely that head-to-head conclusions were impossible without pooling the evidence.

To close that gap, investigators systematically searched PubMed, Cochrane, and Embase for studies published before January 31, 2025, identifying thousands of records: 715 studies touching acalabrutinib, 3,398 on ibrutinib, and 486 on zanubrutinib. After duplicate removal and rigorous screening by independent reviewers, 70 studies survived, comprising four randomized controlled trials, three retrospective-prospective observational studies, and 63 single-arm cohort studies. Together they encompassed 1,641 treatment-naïve patients and 1,791 patients with relapsed or refractory disease, with median ages ranging from 56 to 75 years in the newly diagnosed group and 61 to 74 years in the relapsed group. The analysis was registered with PROSPERO, conducted under PRISMA reporting standards, and quality was assessed with the Cochrane Risk of Bias 2 tool for randomized trials and the MINORS instrument for single-arm studies. Statistical pooling used random-effect models where heterogeneity exceeded an I-squared value of 50 percent, with sensitivity analyses and funnel plots, Egger’s test, and Begg’s test confirming the absence of publication bias.

The headline results are striking. In treatment-naïve patients, BTK inhibitor-based therapy achieved a pooled complete response rate of 76.5 percent and an objective response rate of 94.5 percent. In relapsed or refractory patients, the corresponding figures fell to 43.2 percent and 81.2 percent, illustrating how much harder the disease is to subdue once it has already weathered prior treatment. Subgroup analysis by drug type then revealed a clear hierarchy in the newly diagnosed setting: zanubrutinib delivered a complete response rate of 95.2 percent, acalabrutinib 89.3 percent, and ibrutinib only 61.3 percent, a statistically significant difference with a p-value of 0.0042. Objective response rates followed the same pattern, at 99.1 percent for zanubrutinib, 97.7 percent for acalabrutinib, and 90.0 percent for ibrutinib. In the relapsed setting, however, the three drugs performed comparably, with no significant differences in either complete response or objective response rates.

Safety data from 53 studies added crucial nuance. Hematologic toxicities dominated, with pooled rates of neutropenia around 28 to 34 percent, thrombocytopenia around 33 to 35 percent, and anemia between 16 and 20 percent across patient groups. Zanubrutinib-based therapy showed significantly lower rates of neutropenia in treatment-naïve patients and lower thrombocytopenia in relapsed patients than its two rivals. Infection emerged as the most common non-hematologic adverse event, affecting roughly a third of newly diagnosed patients and nearly 40 percent of relapsed patients, and zanubrutinib carried a notably higher infection rate of 66.1 percent in the relapsed setting. Ibrutinib, by contrast, was associated with a significantly elevated rate of cardiac events at 7.7 percent, compared with just 2.0 percent for acalabrutinib and 0.2 percent for zanubrutinib, while acalabrutinib showed the lowest hemorrhage rate at 9.3 percent. These safety profiles, combined with superior efficacy, argue strongly for the newer agents in frontline care.

The analysis also dissected how best to combine BTK inhibitors with other therapies, a question that has generated considerable confusion in the clinic. In newly diagnosed patients, triple regimens pairing a BTK inhibitor with an anti-CD20 monoclonal antibody and small-molecule agents such as venetoclax, lenalidomide, or proteasome inhibitors achieved a complete response rate of 88.0 percent and an objective response rate of 97.1 percent, numerically outperforming regimens built on traditional chemotherapy with or without stem cell transplantation, though the difference did not reach statistical significance. In relapsed disease, the most impressive complete response rates came from combining BTK inhibitors with CAR T-cell immunotherapy at 80.0 percent, and with anti-CD20 antibodies plus small-molecule therapy at 68.3 percent, both significantly better than monotherapy. Because only 20 patients in the entire dataset received the BTK inhibitor plus CAR-T combination, the authors urge caution in interpreting that result, but the signal is compelling.

The findings carry substantial biological and clinical logic. BTK inhibitor monotherapy rarely achieves deep, durable remissions, and acquired resistance eventually defeats many patients, particularly in the relapsed setting. Pairing BTK blockade with agents attacking complementary pathways, such as the BCL2 inhibitor venetoclax or immunomodulators like lenalidomide, addresses that vulnerability. An observational cohort study cited in the analysis showed that BTK inhibitor-venetoclax regimens could overcome the unfavorable prognosis of TP53-mutated disease, and the ENRICH trial demonstrated that ibrutinib plus rituximab outperformed standard immunochemotherapy with fewer grade 3 or higher adverse events in untreated patients. The meta-analysis now provides quantitative support for chemotherapy-free strategies, showing that small-molecule combinations can match or exceed chemotherapy-based regimens without their cumulative toxicity, a potentially transformative option for elderly and frail patients who cannot tolerate intensive chemoimmunotherapy.

The authors are candid about limitations. Most included studies were single-arm trials vulnerable to selection bias; heterogeneity was moderate to high, reflecting differences in patient demographics, TP53 status, treatment line, and follow-up duration; and most studies did not report progression-free or overall survival in analyzable form, precluding pooled survival analysis and leaving long-term benefit unproven. Nonetheless, the central conclusions stand on robust methodology: acalabrutinib and zanubrutinib are more promising than ibrutinib as first-line options, owing to superior response rates and more favorable safety profiles, and chemotherapy-free combination regimens can partially overcome the traditionally grim prognosis of relapsed disease. As BTK inhibitors continue to infiltrate frontline protocols, this synthesis offers clinicians a data-driven roadmap for sequencing therapy, and it sets a clear agenda for the randomized head-to-head trials that the field still sorely needs.

Subject of Research: Comparative efficacy and safety of Bruton tyrosine kinase inhibitors in treatment-naïve and relapsed/refractory mantle cell lymphoma

Article Title: Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis

Article References: Xu, F., Zou, X., Yang, Y., Zhou, K., & Huang, W. (2026). Comparative Efficacy of BTK Inhibitors in Treatment‐Naïve and Relapsed/Refractory Mantle Cell Lymphoma: A Systematic Review and Meta‐Analysis. Journal of Cellular and Molecular Medicine, 30(17), Article e71340. https://doi.org/10.1111/jcmm.71340

Image Credits: AI Generated

DOI: 10.1111/jcmm.71340

Keywords: mantle cell lymphoma, BTK inhibitors, acalabrutinib, zanubrutinib, ibrutinib, meta-analysis, clinical trials, hematology, chemotherapy-free regimens, lymphoma treatment, venetoclax, CAR-T therapy

The study, led by Sophie van Baalen, Thomas Verra and Michelle Habets of the Rathenau Instituut in the Netherlands, together with colleagues at Wageningen University and Erasmus MC, conducted nineteen semi-structured interviews with scientists working in academia and industry between September 2023 and January 2024. Fifteen of the respondents were academic researchers and four worked for commercial companies, with expertise spanning biomedical research, plant science and microbiology. Using snowball sampling and thematic analysis with Atlas.ti software, the team captured the views of researchers across ten European countries and one respondent from the United States, continuing recruitment until no new themes emerged from the transcripts.

The technical logic behind epigenetic editing explains much of its appeal. Unlike CRISPR-Cas9 gene editing, which slices both strands of the DNA double helix to alter the genetic sequence, epigenetic editing tools such as CRISPR-dCas9 and zinc finger proteins bind to specific DNA sequences without cutting them. Instead of changing the letters of the genetic code, they attach or remove chemical marks on the DNA and its associated proteins, dialing gene activity up or down. Because no DNA breaks are introduced, researchers assume the risk of genomic instability is dramatically reduced. Off-target effects, a persistent worry in gene editing, are viewed as less dangerous in the epigenetic version because misplaced edits do not coincide with strand cuts and may fade over time as the cell’s own machinery reverses the marks.

Respondents also described epigenetic editing as fundamentally more subtle than gene editing. Where gene editing acts like a binary switch, introducing or eliminating genetic functions outright, epigenetic editing was compared to a thermostat that fine-tunes the volume of gene expression. Because cells naturally modify their epigenome constantly as part of ordinary biology, scientists framed the technique as working with, rather than against, the cell’s native processes. Several researchers contrasted this precision favorably with epigenetic drugs, a class of therapeutics that targets epigenetic enzymes broadly and is notorious for lacking specificity. One interviewee emphasized the absence of the translocation problems and genetic instability that plague strand-cutting technologies, noting that unlike base editing, prime editing or conventional gene editing, epigenetic editing never cuts the DNA at all.

Yet the same scientists who endorsed this dominant vision simultaneously questioned its foundations, sometimes without being prompted. The reservations clustered around three scientific uncertainties: reversibility, heritability and complexity. On reversibility, researchers acknowledged that while a limited number of studies have shown epigenetic edits can be reversed or remain stable, it is currently impossible to predict whether an edit at a particular genomic location will persist or vanish, and for how long. This creates an awkward paradox, because the stability needed for durable medical treatments and agricultural applications is exactly what undermines the promised safety net of reversibility. As one respondent explained, scientists do not really know what makes some epigenetic modifications stick around for years while others disappear within days, and following patients long enough to find out would require decades-long cohort studies.

Heritability raised equally thorny questions. For epigenetic editing to work in medicine or agriculture, edits must survive cell division, a property called mitotic heritability, and respondents disagreed about whether they reliably do. The possibility of intergenerational and transgenerational inheritance troubled some biomedical researchers, who worried about unintended effects on the offspring of treated patients, while some plant scientists actually counted on epigenetic edits fading out over generations, reasoning that edited crops escaping into the wild would lose their modifications naturally. The third concern, complexity, struck at the heart of the technology’s predictability. Gene expression is governed by intertwined networks in which cause and effect are not linear; altering an epigenetic mark at one location can trigger cascades of unforeseen changes across hundreds of other genes, especially when the three-dimensional folding of DNA and crosstalk between cells enter the picture. One respondent noted that outside of genomic imprinting, they could not think of a single epigenetic network that is well enough characterized to guarantee a clear therapeutic output.

Despite these doubts, three distinct visions of the technology’s medical future emerged among respondents. The prevailing outlook was hopeful but modest: epigenetic editing could eventually treat cancers driven by epigenetic changes, boost the effectiveness of CAR-T immunotherapies, and address rare diseases caused by epimutations, with early clinical trials restricted to patients who have exhausted all other options. Some argued that medicine routinely advances without fully understanding a drug’s mechanism, so demanding perfection before testing would mean never developing the therapy at all. At the cautious extreme, a minority, particularly basic researchers outside translational work, warned that epigenetic editing could prove less safe than gene editing, since introducing epimutations might reactivate dormant transposons or derail cellular identity in ways scientists can no longer control once edited cells are inside the body. At the opposite pole, a small group envisioned a medical revolution in which epigenetic editors retune multiple genes simultaneously, potentially transforming treatment of autoimmune disease, diabetes, Alzheimer’s and even aging, with speculative applications ranging from skin-rejuvenating creams to cures for HIV and chronic hepatitis B.

The agricultural picture diverged sharply. Plant scientists interviewed for the study did not consider epigenetic editing a commercially viable breeding technology, largely because seed companies require traits that remain stable across generations and environmental conditions, from the controlled greenhouse to the unpredictable open field. Backcrossing can eliminate unwanted off-target changes in plants, removing one of epigenetic editing’s main selling points. Still, respondents sketched hypothetical applications that could eventually prove transformative, such as plant varieties that switch on disease-resistance genes only when a pathogen is actually present, or epigenetic control of flowering, which could dramatically shorten breeding cycles for seed production.

The study’s timing makes its findings particularly pointed. While most respondents questioned whether the technology is ready for real-world deployment, companies are already racing ahead: OMEGA Therapeutics completed a first-in-human clinical trial using epigenetic editing to suppress the oncogene c-MYC in twenty-four participants before filing for bankruptcy in early 2025, and Tune Therapeutics is currently recruiting patients for a trial of an epigenetic silencing therapy for chronic hepatitis B. The authors highlight a mismatch between the private sector’s focus on common, profitable conditions such as high cholesterol and obesity, exemplified by celebrated preclinical results showing durable cholesterol reduction in mice and primates, and the academic community’s caution. They argue that the dominant safety narrative is performing rhetorical work, positioning epigenetic editing as publicly acceptable in ways that may prove premature, and warn of a hype-disappointment cycle reminiscent of the gene therapy backlash of the 1990s. The researchers call for explicit reflexivity within the field, public engagement and citizen participation in shaping the technology’s future, and urge scientists to clearly articulate what evidence is truly needed before epigenetic applications move toward the clinic, arguing that making these visions explicit allows scientists, policymakers and the public to reflect on, adapt and co-create the trajectory of this emerging technology rather than simply inherit whatever future the loudest promises deliver.

Subject of Research: Scientific visions, expectations and reservations regarding epigenetic editing and its responsible innovation

Article Title: Visions, expectations, and reservations in epigenetic editing: towards responsible innovation

Article References: van Baalen, S., Verra, T., Macnaghten, P., Bunnik, E., & Habets, M. G. (2026). Visions, expectations, and reservations in epigenetic editing: towards responsible innovation. Epigenetics Communications, 6(1), Article 6. https://doi.org/10.1186/s43682-026-00047-5

Image Credits: AI Generated

DOI: 10.1186/s43682-026-00047-5

Keywords: epigenetic editing, epigenome, CRISPR-dCas9, gene expression, responsible innovation, gene editing, biotechnology, clinical trials, plant breeding, science and technology studies, research ethics, public acceptance

The authors, led by Ryan M. Kane of Tufts University School of Medicine and the Duke Clinical Research Institute, describe primary care as the “first and last mile” of the US healthcare system. It is where patients first present with symptoms, where prevention and screening happen, and where long-term relationships between patients and trusted clinicians accumulate over years. That structural position, the article contends, makes primary care uniquely suited to generate real-world evidence that reflects the diversity of the population rather than the narrow, highly selected cohorts typical of specialty clinics and academic hospitals. Because care is delivered by general internists, family physicians, pediatricians, and med-peds clinicians across in-person, urgent, and telehealth settings, the patient pool available for research is both enormous and representative.

Recruitment is one of the most concrete advantages the Think Tank identified. Clinical trials frequently stall because they cannot enroll participants quickly enough; recruitment failures and delays are behind an estimated 80% of premature trial discontinuations. Research on trial participation suggests that personalized outreach from trusted recruiters substantially increases patients’ willingness to enroll, and patients consistently report deep trust in their primary care teams—physicians, advanced-practice providers, nurses, and staff. Similarly, physicians are more likely to refer patients to studies when they trust the research team. Embedding recruitment in primary care could therefore shrink timelines and costs while producing cohorts that generalize far beyond a single specialty population.

Primary care also offers scientific opportunities unavailable elsewhere. Because it is the frontline for diagnosis, researchers can study new screening and diagnostic tests in clinically “naïve” patients before specialist referral changes the picture. The setting supports a wide methodological spectrum: pragmatic observational cohorts, implementation science, quality improvement initiatives, phase 4 post-marketing surveillance, and target trial emulation studies that mimic randomized controlled trials through careful patient matching. As demand grows for real-world evidence generated in ordinary care environments rather than artificial experimental conditions, the authors argue that primary care is arguably the most powerful laboratory medicine has yet failed to fully exploit.

Yet the barriers are formidable. The United States has only 67.2 primary care physicians per 100,000 people, compared with 133 in Canada and 114 in Switzerland—countries that achieve better population health outcomes at lower national expenditure. The workforce shortage is driven by high educational debt, lower salaries than subspecialties, burnout from excessive documentation and short visits, and an aging physician population. The arithmetic is stark: one widely cited analysis estimates that fully delivering guideline-recommended care to a typical adult panel would require 27 hours per day. Clinicians operating at that level of overload have little capacity to participate in research, and the pipeline of new primary care researchers is dwindling accordingly.

Infrastructure and money compound the workforce problem. Effective primary care research requires trained clinical and non-clinical staff to handle regulatory documentation, recruitment, data collection, and participant navigation, along with sustained bidirectional communication between research teams and practices. Systematic reviews cite missing dedicated time, limited research training and confidence, and weak administrative support as recurring obstacles. Funding has grown more precarious, not less: federal freezes and workforce reductions have hit agencies with a historic commitment to primary care research, notably the Agency for Healthcare Research and Quality, whose grant function analysts have described as collapsing under impoundments. Incentives add another layer of misalignment—fee-for-service reimbursement rewards clinical throughput, and with roughly four out of five physicians now employed by hospitals, health systems, or corporations, practice consolidation prioritizes revenue over research participation.

The Think Tank’s first proposed solution is to scale up practice-based research networks, or PBRNs. These networks embed longitudinal research infrastructure into community-based primary care by connecting clinics to an operational hub, often based at an academic medical center, that supplies onsite research staff, training, and facilitation. In their foundational description, Westfall and colleagues argued that PBRNs can identify the gaps between recommended and actual care, test whether efficacious treatments remain effective in real ambulatory settings, and serve as laboratories for system improvement. Evidence suggests PBRNs improve recruitment, reduce clinician burden, and generate more generalizable evidence, while community-based participatory approaches build durable relationships among researchers, clinicians, staff, and patients.

Existing national networks demonstrate the model’s scale. PCORnet, the Patient-Centered Clinical Research Network funded by the Patient-Centered Outcomes Research Institute, links more than 75 health systems through thousands of academic, community, and federally qualified health centers, with standardized electronic health record data on over 45 million patients seen in the past year. That combination of rural and urban representation and standardized data makes such networks suitable for everything from large multisite pragmatic trials to rare disease studies. The Think Tank also emphasized a second lever: technology. Interoperable EHRs with built-in artificial intelligence, secure patient portals for identifying and contacting eligible participants, digital consent and randomization platforms, EHR-embedded interventions, and remote collection of patient-reported outcomes and wearable data can all engage participants asynchronously and minimize disruption to busy practices. The authors caution, however, that digital approaches risk worsening technology-related health disparities, particularly in rural areas, and must be deployed deliberately.

The third pillar is investment. Because primary care practices are pressured by high daily clinical throughput, financial remuneration is needed to offset research-related losses in clinical revenue, along with resources for health information technology, laboratory processing, and startup costs. The authors call for expanded public, private, and nonprofit funding for research training at every career stage—fellowships comparable to those routinely funded in specialty medicine, training for non-clinician researchers, and short-term or asynchronous programs for practicing clinicians—so that research can be embedded without destabilizing patient care.

The article’s conclusion is blunt: strengthening primary care research is a scientific imperative, not an optional reform. With chronic disease at the center of national health policy debates, the setting best positioned to deliver prevention, coordinate care, and reach the whole population remains almost entirely disconnected from the machinery of evidence generation. Research networks, digital tools, and sustained funding, the authors argue, are the three levers that can close the gap between where Americans receive care and where knowledge is made. If the enterprise takes that prescription seriously, the waiting room may become one of the most productive research spaces in medicine.

Subject of Research: Integrating clinical research into primary care through practice-based research networks, digital health technology, and increased funding

Article Title: Rewiring the Research Enterprise: Why Primary Care Is the Next Frontier

Article References: Kane, R. M., Jackman, J. G., Henningfield, M. F., Hester, C. M., Cherrington, A. L., Sanchez, K., Tapp, H., Hornik, C. P., Hernandez, A. F., Dolor, R. J., & Rothman, R. L. (2026). Rewiring the Research Enterprise: Why Primary Care Is the Next Frontier. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10760-5

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10760-5

Keywords: primary care, clinical research, practice-based research networks, real-world evidence, clinical trials, PCORnet, digital health, workforce shortage, research funding, learning healthcare system, chronic disease, implementation science

The central insight behind optogenetic therapy is elegantly simple. In advanced retinal degenerative diseases such as retinitis pigmentosa and end-stage age-related macular degeneration, the photoreceptors that normally convert light into electrical signals have degenerated, leaving the rest of the retinal circuitry largely intact but functionally dark. Conventional gene replacement therapy, which works by delivering a healthy copy of a single defective gene, is no longer applicable once the target cells are gone, particularly because these diseases can be caused by mutations in dozens of different genes. Optogenetics sidesteps this problem entirely: it is mutation-agnostic. By using viral vectors to deliver genes encoding light-sensitive proteins called opsins into whatever neurons remain, the therapy converts those cells into artificial photoreceptors capable of responding to light directly.

The technical foundation of the field was established in the mid-2000s, when researchers demonstrated that channelrhodopsin-2, a directly light-gated cation channel originally discovered in algae, could be expressed in neurons to control their activity with millisecond precision. Early proof-of-concept studies showed that ectopic expression of microbial-type rhodopsins could restore visual responses in mice with photoreceptor degeneration, and landmark work soon extended this approach to ON bipolar cells and to dormant cone photoreceptors in models of retinitis pigmentosa. What began as a neuroscience tool for controlling neural activity has since evolved into a therapeutic platform, with the retina emerging as arguably the most clinically advanced target for optogenetics in the entire human body.

One of the most consequential decisions in any optogenetic therapy is which retinal cell type to target. The review devotes detailed attention to this question, weighing the merits of retinal ganglion cells, bipolar cells, and residual cone photoreceptors. Ganglion cells, the output neurons of the retina, are readily accessible from the vitreous and survive late into degeneration, but targeting them means bypassing the retina’s internal image-processing circuitry entirely. Bipolar cells sit one synapse upstream and offer the possibility of preserving some of the retina’s native signal processing, potentially yielding better spatial resolution and more natural vision. Residual cones, even when metabolically compromised, can in principle be genetically reactivated and their existing downstream wiring exploited. Each strategy involves distinct trade-offs between accessibility, image fidelity, and light sensitivity, and no single approach has yet emerged as definitively superior.

Opsin engineering itself has progressed dramatically. First-generation tools such as channelrhodopsin-2 respond only to high-intensity blue light, far brighter than ambient levels, which is a fundamental problem for a therapy intended to work under everyday conditions. Subsequent generations have addressed this through several routes: microbial opsins with enhanced sensitivity, animal cone rhodopsins that exploit the retina’s natural biochemical amplification cascades, and engineered multicharacteristic opsins designed to combine fast kinetics, broad spectral sensitivity, and high responsiveness. Chimeric rhodopsins have shown highly sensitive visual restoration and even neuroprotective effects in mouse models, while rhodopsin-based approaches have demonstrated that enhanced sensitivity and adaptation can be achieved by recruiting the native phototransduction machinery. The review emphasizes that light sensitivity remains perhaps the single most important determinant of whether laboratory success translates into meaningful patient benefit.

Delivering these genes to the right cells presents its own formidable engineering challenge, and the review provides a thorough account of the viral vector platforms underpinning retinal gene delivery. Adeno-associated virus, or AAV, has become the workhorse of retinal gene therapy thanks to its safety profile, durability, and natural ocular tropism. Engineered capsids such as AAV7m8 and the directed-evolution variant AAV8BP2 have enabled efficient outer retinal gene delivery from a simple intravitreal injection, avoiding the surgical risks of subretinal administration. Yet AAV’s roughly 4.7-kilobase packaging limit constrains how large an opsin gene, promoter, and regulatory elements can be squeezed into a single vector. Creative solutions, including intein-mediated protein trans-splicing that splits large proteins across two vectors and reconstitutes them inside the target cell, are expanding what is possible, while cell-specific promoters drawn from retinal ganglion cell and bipolar cell biology sharpen targeting precision.

The clinical pipeline reflects this maturation. A watershed moment came in 2021, when researchers reported partial recovery of visual function in a blind patient with retinitis pigmentosa after optogenetic therapy using the opsin ChrimsonR combined with image-transmitting goggles, the first reported functional benefit in a human. Since then, multiple clinical trials have advanced worldwide, including studies of AAV-based RGS-optimized therapies, the STARLIGHT phase 2 trial of MCO-010 multicharacteristic opsin therapy in patients with Stargardt disease, and trials of programs including GS030, BS01, ZM-02 and RV-01 targeting advanced retinitis pigmentosa. Work in non-human primates has demonstrated high spatiotemporal resolution and pattern discrimination compatible with genuine vision restoration, providing critical evidence that the approach can scale from rodents to human-sized eyes.

Yet the review is notably candid about the barriers that remain. Interspecies differences loom large: the mouse retina, the workhorse of preclinical optogenetics, differs radically from the human retina in cell numbers, photoreceptor topography, and internal anatomy, meaning promising rodent results do not guarantee human efficacy. The primate eye poses additional physical barriers, including the internal limiting membrane and the vitreoretinal interface, which impede vector penetration from the vitreous. Immune responses represent another serious concern, both to AAV capsids, which many patients have already encountered naturally, and to the microbial opsin proteins themselves, which the human immune system may recognize as foreign. Neural remodeling in the degenerated retina further complicates matters, as surviving circuits rewire in ways that may distort or degrade the signals delivered by engineered photosensitivity.

Perhaps less appreciated, but equally consequential, are the drug-development and regulatory hurdles. Patients with profound visual impairment present unique challenges for clinical trial design, and the field currently lacks standardized, validated clinical endpoints for measuring meaningful visual improvement in people with end-stage retinal degeneration. Traditional visual acuity measures are largely useless at these levels of vision loss, forcing investigators to develop novel outcome measures, from light-perception tasks to mobility and object-recognition tests, and to work closely with regulatory agencies and patient advocacy groups to define what constitutes a clinically meaningful benefit in a rare-disease population.

The review concludes that addressing these barriers is essential to establishing optogenetics as a clinically viable therapeutic modality and to enabling next-generation vision restoration. The trajectory is nonetheless striking: in barely two decades, optogenetics has moved from millisecond optical control of neurons in a dish to a growing international clinical pipeline offering realistic hope to patients for whom no other treatment exists. As opsin sensitivity improves, engineered capsids deliver genes more safely and precisely, and clinical endpoints mature, the prospect of restoring useful vision to millions of people blinded by photoreceptor degeneration is shifting from speculative ambition to an achievable clinical goal, one light-sensitive cell at a time.

Subject of Research: Optogenetic gene therapy for restoring vision in advanced retinal degenerative diseases

Article Title: Optogenetic vision restoration: translational barriers and emerging therapeutic strategies

Article References: Nakada, N. (2026). Optogenetic vision restoration: translational barriers and emerging therapeutic strategies. Gene Therapy. https://doi.org/10.1038/s41434-026-00640-2

Image Credits: AI Generated

DOI: 10.1038/s41434-026-00640-2

Keywords: optogenetics, vision restoration, gene therapy, retinitis pigmentosa, retinal degeneration, opsins, adeno-associated virus, retinal ganglion cells, bipolar cells, photoreceptors, clinical trials, blindness